Physician profile
Muhammad U Khan
NPI 1265840334
$7,831.79
in general payments reported to CMS, 2019-2025
24 companies · $2,038 in 2025
The $2,038 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.27 · 2021: $2,279 · 2022: $1,302 · 2023: $2,041 · 2024: $95.45 · 2025: $2,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882 · Grant: $1,126 · Travel and Lodging: $824 · Education: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.34 |
| Grant | $1,126.43 |
| Travel and Lodging | $824.46 |
| Education | $340.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,017.64 | 2021-2023 | Ensite |
| Boston Scientific Corporation | $1,952.13 | 2021-2025 | Versacross Access Solution, Avvigo Guidance System, Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $700.33 | 2025 | Turbohawk, Venaseal |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $455.21 | 2021-2023 | Lifevest |
| Amgen INC. | $355.69 | 2021-2024 | Repatha |
| Biotronik INC. | $240.84 | 2021-2025 | Biomonitor, Amvia Edge |
| Astrazeneca Pharmaceuticals Lp | $188.57 | 2023-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $116.46 | 2021 | |
| Merck Sharp & Dohme LLC | $112.84 | 2025 | Verquvo |
| Cardiva Medical, INC. | $100.20 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Novartis Pharmaceuticals Corporation | $90.16 | 2025 | |
| Cardiovascular Systems INC. | $77.27 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $67.52 | 2025 | Camzyos |
| Penumbra, INC. | $63.06 | 2023 | Indigo System |
| Bayer Healthcare Pharmaceuticals INC. | $54.79 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $47.66 | 2025 | |
| Baxter Healthcare | $43.91 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Teleflex LLC | $33.34 | 2023 | Supercross |
| Atricure, INC. | $29.12 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Novo Nordisk INC | $23.33 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $18.61 | 2024 | |
| Esperion Therapeutics, INC. | $16.97 | 2025 | Nexletol |
| Kestra Medical Technology Services, INC. | $14.87 | 2024 | Assure Wcd |
| Tactile Systems Technology INC | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.